MyoKardia is dedicated to revolutionizing the treatment of genetic heart diseases. The company's initial focus includes hypertrophic and dilated cardiomyopathy (HCM and DCM), diseases for which there have been no treatment advances in more than 50 years.
By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to usher in an era of precision medicine that will dramatically improve the treatment of cardiomyopathies and make a meaningful difference in the lives of millions of people suffering from cardiovascular diseases. Available treatments for patients suffering from these forms of heart disease have been approved for other illnesses and only treat the symptoms of their disease. MyoKardia’s approach targets the genetic mutations that are the underlying causes of cardiomyopathy, addressing the fundamental mechanisms of the disease. This genetically targeted approach has the potential to revolutionize the treatment of cardiomyopathies, and ultimately a broader spectrum of cardiovascular disease, including heart failure.
MyoKardia was launched in 2012 by experts in cardiovascular disease genetics and muscle biology, who are acknowledged as the world leaders in their fields and are harnessing biology-based innovation to create new kinds of medicines.
In 2014, MyoKardia forged a strategic worldwide collaboration with Sanofi to discover, develop and advance first-of-its-kind targeted therapeutics for HCM and DCM. The company is backed by funding from leading healthcare investor Third Rock Ventures.